Compare Abeona Therapeutics Inc (ABEO) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Core S&P 500 ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while iShares Core S&P 500 ETF trades at $747.96. Which is the better fit depends on your goals.
| ABEO | IVV | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $763.10 |
52-Week Low | $4.17 | $623.33 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
IVV, tracking the S&P 500, trades at $754.80, up 0.87% with a bullish technical signal from moving averages. The ETF shows strong institutional backing with $886 billion in assets and a low 0.03% expense ratio. Recent sector rotation has pressured tech stocks, but broader market optimism persists with analysts targeting S&P 500 levels up to 8,800 by year-end.
The outlook remains positive given strong earnings growth expectations and reasonable valuations, though concentration risk in top holdings and potential summer volatility pose near-term challenges. IVV offers efficient exposure to US large-caps, with dividend distributions providing additional return potential for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
